J&J signs deal with Fate for offtheshelf immunotherapies

J&J signs deal with Fate for off-the-shelf immunotherapies

Fate Therapeutics and J&J will collaborate to progress candidates against four tumor-associated antigens.

Original Article: J&J signs deal with Fate for off-the-shelf immunotherapies

More From BioPortfolio on "J&J signs deal with Fate for off-the-shelf immunotherapies"